/C O R R E C T I O N — Nycomed/LISBON, Portugal - In the news release, “First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain” issued on 9 Sep 2009 07:00 GMT, by Nycomed over PR Newswire, we are advised by a representative of the company that the first set of bullet points should read “The median number of BTCP episodes per patient per day was 3; Each episode had a median duration of 60 minutes; 96% of the pain episodes were described as moderate to severe; For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people” and the second set of bullet points should read “At least 95% of patients were using orally administered drugs; “The time to first noticing a reduction in pain had a median time of 20 minutes; In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes”. In addition, the fourth paragraph should read “For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes” instead of “For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes” as incorrectly transmitted by PR Newswire. Complete, corrected release follows: The Mind Games Smokers Play When Trying to Quit Revealed in New SurveyLONDON - LONDON, September 8 /PRNewswire/ – - New NiQuitin(R) Pre-Quit(TM) Lozenges Launched To Help Smokers Address Their Internal Struggle By Easing Into Quitting Oprah’s Long Time Make-Up Artist Throws a HissyfitMELBOURNE, Australia - Reggie Wells, the Emmy award winning make-up artist, who has been the man behind the face of global media sensation Oprah Winfrey for more than 20 years, has been appointed International Creative Director of Australia’s hottest new beauty brand, Hissyfit. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharmaLONDON - The 2009 Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award is presented to Pronova BioPharma ASA. The company’s first commercialised product is the first and only EU-and FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe and Asia and Lovaza in the USA, the product is a prescribed adjunct to diet for the treatment of elevated levels of triglycerides in humans. In addition, Omacor/Lovaza has the approval in certain markets for treatment of the secondary prevention of post-myocardial infarction. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus ChallengeBOZEMAN, Montana - LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo. Clinical studies to date have shown the vaccine to be immunogenic and generally well tolerated in human subjects. Update on Velaglucerase AlfaCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide. Cell Biosciences Signs Agreement to Acquire Alpha InnotechSANTA CLARA, California - Cell Biosciences, Inc. and Alpha Innotech Corp. (OTC Bulletin Board: APNO) today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for US$1.50 per share or approximately US$17.9 million in cash. This acquisition would significantly expand Cell Biosciences’ protein analysis business to include a global infrastructure and a broad protein analysis product portfolio. OAG Releases Prototype for Pandemic Disease Planning and ManagementCHICAGO - - Modelling Air Travel Could Prove Critical for Health Organizations and Government Agencies Preparing for the Upcoming Flu Season Bounty Parenting Club Launches View on Demand ‘How to Breastfeed’ VideoLONDON - Bounty, the UK’s favourite parenting club, today launches a 4 minute ‘How to Breastfeed’ online video clip to help expectant and new mums take a real life, close up peek at how a baby ‘latches on’ to the breast when feeding. REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive BladderLONDON - Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7). Tosho’s Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I.V. Automation Strategic PartnershipBOZEN, Sud-Tyrol, Italy - Health Robotics today announced that after a successful first year of cooperation in Japan with Tosho Inc., the companies signed this week a contract renewal of the CytoCare(TM) and i.v.STATION(TM) exclusive distribution agreements, and an expansion of their strategic relationship to include future joint-development projects in their respective areas of Pharmacy Automation expertise. Home-Spun or Hard Fact?NEWBURY, England - - Fast-Food Family Planning May Contribute to High Levels of Unintended Pregnancies Helix BioPharma Announces CDN$13.5 Million Private PlacementAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at CDN$2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009. Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSTOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development’s business strategy. Nielsen Wins “Most Innovative Approach” at the Best of Business Intelligence (BOBI) AwardsLONDON - - Nielsen’s BuzzMetrics Analysis of Consumer Experience to Influence Marketing Decisions for Pfizer’s Smoking Cessation Product - Champix - Cited by Judges as a Unanimous and Clear Winner A Fifth of People With MDS (Blood Cancer) Die Prematurely Because the NHS Won’t Fund New Life-extending DrugsLONDON - - More Than Half of Blood Cancer Experts (56 Percent) say Less Priority is Given to Rarer Cancers Compared to Other Common Cancers Nucletron Increases Full Year Outlook After Strong First Half 2009VEENENDAAL, the Netherlands - - Despite Challenging Global Economic Conditions, Nucletron Surpassed Projections for the First Half Year Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17PHILADELPHIA - - INTUNIV, the First Nonscheduled alpha-2A receptor agonist indicated for ADHD, Demonstrated Improvement in a Range of ADHD Symptoms That can be Disruptive, Such as Inattention, Arguing With Adults, Hyperactivity, Impulsivity, and Losing One’s Temper CryoLife’s Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the WorldATLANTA - - The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare ConferenceAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company’s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company’s website, www.helixbiopharma.com, on September 9th, 2009. Health Workers Face Postcode Lottery for Swine Flu Vaccine, Chemist+Druggist RevealsTONBRIDGE, England - Thousands of frontline health workers in England are trapped in a postcode lottery after Department of Health (DH) guidance on swine flu vaccination has left local health chiefs confused over who is eligible for the jab. Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for LongerMAIDENHEAD, England - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Ex-smokers can win a HolidayLONDON - Ex-smokers across the UK still have time to enter stop smoking charity QUIT’s competition to find the country’s most inspirational quitters and win a holiday. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RABASEL and REINACH, Switzerland - - CAPRA-2-Data Will be Used to File for US Marketing Approval Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 InhibitorsBARCELONA, Spain - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & SullivanLONDON - Although most hospitals in Europe have some kind of information system in place, very few have a fully integrated and functional hospital information systems (HIS) solutions installed. The adoption rate of HIS solutions in 2008 in Europe varied from about 73.0 per cent in Italy and Spain to 95.0 per cent in Scandinavia. Increasing accountability pressures on the government and regulatory authorities to garner more investments into healthcare IT adoption is boosting the HIS market potential. BMI Healthcare Hospitals Offer Free Blood Pressure Checks and Advice During Know Your Numbers! Week (7-13 September)LONDON - - With Photo - One in Three People Have High Blood Pressure; Over Five Million Don’t Know it MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global Emerging Lighting Technologies Market (2009-2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global emerging lighting technologies market is expected to be worth US$112.2 billion by 2014, recording an estimated CAGR of 7.9% from 2009 to 2014. The North American market is expected to account for nearly 39% of the total revenues. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014WILMINGTON, Delaware - According to a new healthcare market research report ‘Global Top Minimally Invasive/Non Invasive Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), in 2009, the global minimally invasive/ non invasive market is estimated to be approximately $16.4 billion and is expected to reach $24.4 billion by 2014 at a CAGR of 8.3%. Accumetrics, Inc. Forms Partnership With Grifols as Its Distributor in Spain, Portugal and ChileSAN DIEGO - Accumetrics, Inc. has announced the signing of a new exclusive distribution agreement for its VerifyNow(R) System in Spain, Portugal and Chile with Grifols S.A.. This distribution agreement will continue to expand Accumetrics’ reach in both scope and geography, and add to the growing numbers of countries where physicians have access to the VerifyNow System. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III TrialsCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints. Aircraft Reports Material Expansion and Staff IncreaseEDINBURGH, Scotland - Aircraft Medical (Aircraft), the UK medical devices company, announces that it has added 25 new staff to its R&D, business development and sales teams since January 2009. MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure ProgressionNATICK, Massachusetts and BARCELONA, Spain - - Results of Landmark Heart Failure Trial Published by New England Journal of Medicine and Presented at ESC Two Powerful Companies, One Powerhouse in ProtectionPARIS - After one of the most significant acquisitions in hand protection manufacturing history, Showa Best Glove has emerged as the result of the operational integration of Showa Europe and Best Manufacturing Europe. “Our two-company integration in Europe is complete with the formation of Showa Best Glove,” said Yasuo Fukuda, the President of Europe for Showa Best Glove. “We are now able to deliver on the potential we outlined when Showa Glove acquired Best Manufacturing in 2007.” SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical CompanyAMSTERDAM - SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company. |
